Improving Health by Pioneering Non-Invasive Technologies
Failure to detect diseases early-on has a significant impact on visual outcomes, health care costs, and quality of life.
What if we could intervene sooner?
The eye is a unique window into a person’s health. Zilia’s technology harnesses the power of light to assess biomarkers associated with ocular, neurological, and systemic conditions. It holds the potential to empower scientists and health care professionals with new clinical information.
How Does it Work?
01. Patient Assessment
- Light emitted from the device travels through the eye and reflects on the eye fundus.
02. Spectral Analysis
- The light signal that returns is analyzed to provide a series of images and high-quality spectra.
03. In-depth Insight
- Data is processed in real-time and actionable biomarker data is presented in a user-friendly interface.
What is Spectrometry?
A portion of the light reflected from the eye fundus is used for imaging while the other portion provides reflectance spectra, which act as fingerprints for the targeted tissue. These spectra are then processed in real-time for the quantification of relevant biomarkers.
Generating Value in Health Care
Too often, ocular diseases are diagnosed late because current tools have low sensitivity or can only assess existing damage to the eye. By quantifying key biomarkers, eye care professionals will have access to meaningful insight, allowing for earlier diagnosis, detailed prognosis, and better treatment.
Enabling researchers to effectively measure biomarkers in the eye paves the way for helping identify at-risk populations, improving the management of various diseases, and developing new therapies.
With its non-invasive technological platform, Zilia provides unprecedented data, enabling pharmaceutical companies to better direct their resources to create and validate more efficient drugs at a quicker pace.